Amneal Pharmaceuticals vs Teva Pharmaceutical Industries
AMRX and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and TEVA compare
Teva Pharmaceutical Industries is the larger company, worth 7.0 times as much as Amneal Pharmaceuticals ($48.3B against $6.9B).
On earnings, Amneal Pharmaceuticals is cheaper: it trades at 43.9× trailing earnings, against 69.1× for Teva Pharmaceutical Industries.
Amneal Pharmaceuticals grew revenue faster over the last twelve months (9.3% versus −15.2% for Teva Pharmaceutical Industries).
Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with 5.0% at Teva Pharmaceutical Industries.
Amneal Pharmaceuticals scores higher on the StockData Score (10 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $6.9B | $48.3B |
| Share price | $21.51 | $41.47 |
| Change, 1 year | 106% | 110% |
| Change, 5 years | 318% | 354% |
| Beta (5Y) | 1.06 | 0.99 |
| Employees | 8,500 | 34K |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 43.9× (better) | 69.1× |
| P/S | 2.2× (better) | 3.4× |
| P/B | 208× | 6.2× (better) |
| EV/EBITDA | 20.5× | 19.0× (better) |
| P/FCF | 53.7× | 35.8× (better) |
| FCF yield | 1.9% | 2.8% (better) |
| Fair value | $12.75 | $18.65 |
| Margin of safety | −68.7% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | 9.3% (better) | −15.2% |
| Revenue growth, 5Y average | 8.7% (better) | 0.71% |
| Net income growth (TTM) | 4563% | – |
| EPS growth (TTM) | 4800% | – |
| EPS growth, 5Y average | −18.5% | – |
| Profitability | ||
| Gross margin | 39.3% | 64.4% (better) |
| Operating margin | 14.6% (better) | 11.4% |
| Net margin | 5.0% (better) | 5.0% |
| FCF margin | 4.1% | 9.6% (better) |
| Return on equity | – | 9.7% |
| Return on invested capital | 20.3% | 23.0% (better) |
| Financial health | ||
| Debt / equity | 77.83 | 0.58 (better) |
| Net debt / EBITDA | 5.38 | 0.33 (better) |
| Current ratio | 2.20 (better) | 0.88 |
| Altman Z-score | 2.51 (better) | 0.84 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 52.7% | – |
| Held by insiders | 60.7% | 0.43% |
| Insider net buying, 12 months | −$9.8M (better) | −$113M |
| Short interest, % of float | 9.0% | 2.6% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.